Not yet recruitingInterventionalPhase 2Last updated Aug 14, 2026

Study of SG301 for Renal AMR After Transplantation

A Phase II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Efficacy of SG301 Injection in Patients With Antibody-Mediated Rejection (AMR) After Renal Transplantation

Overview

ClinicalTrials.gov ID: NCT07764627
Lead Sponsor: Hangzhou Sumgen Biotech Co., Ltd.INDUSTRY
Brief Summary: To evaluate the safety and tolerability of SG301 injection in patients with antibody-mediated rejection (AMR) after renal transplantation.
Study Type: Interventional

Status

Overall Status: Not yet recruiting
Start Date: Sep 1, 2026Estimated
Primary Completion Date: Mar 31, 2027Estimated
Completion Date: Jun 30, 2028Estimated

Study Record Dates

First Submitted: Aug 10, 2026
First Submitted that Met QC Criteria: Aug 12, 2026
First Posted: Aug 14, 2026Actual
Last Update Submitted that Met QC Criteria: Aug 12, 2026
Last Update Posted: Aug 14, 2026Actual
Last Verified: Aug 2026

NCT06503731Active, not recruiting

A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)

NCT06744647Active, not recruiting

Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation

NCT03221842Terminated

Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients

NCT03380936Terminated

Pilot Study of Treatment for Subclinical AMR (Antibody-mediated Rejection) in Kidney Transplant Recipients

NCT06090799Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3032 in Healthy Subjects

NCT07000292Not yet recruiting

MSC303 Subcutaneous Injection for the Treatment of Immunologic Glomerular Disease.